AddedRisk Factors
drugs, surgical procedures, and other treatments in particular, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
AddedRisk Factors
Regulatory standards are subject to change over time, making it difficult to accurately predict the likelihood of marketing approval even when clinical trials meet their endpoints.
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
AddedRisk Factors
Regulatory standards are promulgated by various government entities and are subject to change based on factors such as scientific developments, public perceptions of risk, and political forces. Because clinical trials often take years to complete, it is sometimes possible for standards that exist during the conception and initiation of a clinical trial to change before the clinical trial is completed or reviewed by government regulators. For example, we may initiate clinical trials that are designed to show benefits on relatively short-term endpoints, but ultimately be required to show benefits in longer-term outcome studies. While some government entities have safeguards intended to ensure standards agreed upon by sponsors and regulators at the outset of a clinical trial are applied during regulatory review processes, those safeguards generally permit regulators to apply more rigorous standards where regulators believe doing so is necessary. As such, there can be no assurance that regulatory standards that are appropriate at the outset of a clinical trial program will not become more rigorous during the regulatory approval process and could potentially result in a delayed approval or denial of marketing authorization.
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
AddedRisk Factors
In addition, the FDA, EMA and other regulatory authorities may change their policies, issue additional regulations or revise existing regulations, or take other actions, which may prevent or delay approval of our future products under development on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain approvals, increase the costs of compliance or restrict our ability to maintain any marketing authorizations we may have obtained. In June 2024, the Supreme Court overruled the Chevron doctrine, which had given deference to regulatory agencies’ statutory interpretations of ambiguous regulations in litigation against federal government agencies, such as the FDA. The overruling of the Chevron doctrine may significantly increase the number of challenges brought by companies and other stakeholders against federal agencies such as the FDA and its longstanding decisions and policies, including the FDA’s statutory interpretations of market exclusivities and the “substantial evidence” requirements for drug approvals, which could undermine the FDA’s authority, lead to uncertainties in the industry, and disrupt the FDA’s normal operations, any of which could delay the FDA’s review of our regulatory submissions. We cannot predict the full impact of this decision, future judicial challenges brought against the FDA, or the nature or extent of government regulation that may arise from future legislation or administrative action.
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
RemovedRisk Factors
•The regulatory approval processes of the FDA and comparable foreign authorities are lengthy and inherently unpredictable.
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedRisk Factors
•Our products remain subject to regulatory scrutiny even if we obtain regulatory approval.
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedRisk Factors
•Our employees or consultants may engage in misconduct which could cause significant liability for us.
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedRisk Factors
•continue to establish or grow a marketing and distribution infrastructure and field force to commercialize our products and any product candidates for which we may obtain marketing approval;
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedRisk Factors
•continue to operate as a public company and comply with legal, accounting and other regulatory requirements;
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedRisk Factors
•launching and commercializing our products and product candidates for which we obtain regulatory and marketing approval, either directly or with a collaborator or distributor;
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedRisk Factors
•obtaining market acceptance of our products and product candidates as viable treatment options;
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedRisk Factors
•the scope, rate of progress, results, and cost of our clinical studies, nonclinical testing, and other related activities;
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedRisk Factors
•the cost of creating additional infrastructure, including facilities and systems, such as systems in our GMP gene therapy manufacturing facility;
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedRisk Factors
•the cost and timing of establishing and operating our international subsidiaries;
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedRisk Factors
•the cost and timing of establishing and operating field forces, marketing, and distribution capabilities;
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedRisk Factors
•the cost and timing of other activities needed to commercialize our products; and
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RewordedRisk Factors
In particular, our operations are directly, and indirectly through our customers, subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, the federal False Claims Act, and physician sunshine laws and regulations; and patient and non-patient privacy laws and regulations, including the European General Data Protection Regulation (EU) 2016/679, or GDPR, in the EEA, the GDPR as incorporated into UK law pursuant to the European Union (Withdrawal) Act 2018, or the UK GDPR, in the UK, the Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, the California Consumer Privacy Act, Act of 2018, or CCPA, including amendments from as amended by the California Privacy Rights Act, Act of 2020, or CPRA, and California’s Confidentiality of Medical Information Act; and the evolving global landscape for AI-related laws and regulations, which may impose obligations on companies developing and using AI and include U.S. federal and state laws and regulations and the EU Artificial Intelligence Act, as described above in “Item 1.
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
RewordedRisk Factors
Furthermore, geopolitical tensions with China China, including the Congressional legislative proposal, titled the recently enacted BIOSECURE Act, which would, which, among other things, prohibit prohibits U.S. federal funding in connection with biotechnology equipment or services produced or provided by Chinese biotechnology companies, certain designated “biotechnology companies of concern” as determined by the Office of Management and the recent requests by certain Congressional leaders that WuXi AppTech Co. Budget, , could lead to our competitors and its affiliates be added other companies moving to certain U.S. suppliers outside of China, including to our current suppliers.
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
RewordedRisk Factors
The GDPR imposes and UK GDPR impose a number of strict obligations and restrictions on the ability to process requirements for processing personal data of individuals, in particular with respect to special categories of personal data like health data individuals (e.g., reliance on a legal basis, information to individuals, notification to relevant national data protection authorities in case of personal data breach and implementation of appropriate security measures). measures), in particular with respect to special categories of personal data like health data which is subject to specific requirements.
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
RewordedRisk Factors
The confidentiality agreements entered into with our employees, consultants, scientific advisors, contractors and other third parties that we rely on in connection with the development, manufacture and commercialization of our products may not be sufficient to protect our proprietary technology and processes, which increase the risk that such trade secrets may become known by our competitors or may be inadvertently incorporated into the technology of others. processes.
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
RewordedRisk Factors
Cybersecurity incidents increasingly involve the use of AI and machine learning to launch more automated, targeted and coordinated attacks on targets. targets, and the use of AI by us or the third parties on which we depend to operate our business may create new cybersecurity vulnerabilities, including those which may not be recognized at this time.
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
RewordedRisk Factors
We are aware of certain U.S. and foreign patents owned by third parties that a court might construe to be valid and relevant to certain methods that may be used in the manufacture or delivery of one or more of our gene therapy product candidates, certain methods that may be used in their manufacture or delivery, or certain formulations comprising one or more of our gene therapy candidates.
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
RewordedRisk Factors
There In the US, there are also several compliance requirements under the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, HIPAA/HITECH and implementing regulations that create requirements relating to the privacy and security of protected health information.
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
RewordedRisk Factors
In such an event, Results of our studies could be suspended or terminated, investigator-sponsored trials that reveal a high and unacceptable severity and prevalence of adverse side effects can lead to suspension or termination, and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny or withdraw approval of our product candidates for any or all targeted indications.
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
RewordedRisk Factors
Investors who are focused on ESG matters may seek enhanced to modify our current ESG disclosures and practices or to implement policies that are costly or adverse to our business, and there can be no assurances that stockholders they will not advocate, via proxy contests, media campaigns or other public or private means, for us to make corporate governance certain changes or engage in certain corporate actions. actions on these topics.
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all, particularly which are often impacted by changes in light of the current macroeconomic conditions, including changing interest rates rates, inflation and inflation. market instability arising from political and trade tensions (including government shutdowns).
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
RewordedRisk Factors
To the extent that any disruption or security breach results in a loss of or damage to our data or applications, loss unauthorized access, use or disclosure of trade secrets or inappropriate disclosure of secrets, other confidential or proprietary information, including protected health information, or other personal information of employees or former employees, information, unauthorized access to our clinical data, or disruption of the manufacturing process, we could incur liability and the further development of our drug candidates could be delayed.
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
RewordedRisk Factors
Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or if we have specific strategic considerations.
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Under the EU Patent Package, we will have the right to opt our patents out of the UPC over the first seven years of the court’s existence, but doing so may preclude us from realizing some of the benefits of the new unified court.
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
AddedMD&A
Year Ended December 31, Dollar Percent 2025 2024 Change Change Clinical programs: Gene therapy programs DTX301 $ 27 $ 41 $ (14) -34% DTX401 60 75 (15) -20% UX701 30 33 (3) -9% UX111 94 41 53 129% CMC costs 9 4 5 125% Total gene therapy programs 220 194 26 13% Biologic and nucleic acid programs GTX102 72 51 21 41% UX143 147 89 58 65% Total biologic and nucleic acid programs 219 140 79 56% Translational research 39 46 (7) -15% Upfront license, acquisition, and milestone fees — 30 (30) -100% Approved products 37 35 2 6% Infrastructure 79 81 (2) -2% Stock-based compensation 84 87 (3) -3% Other research and development 72 85 (13) -15% Total research and development expenses $ 750 $ 698 $ 52 7%
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
AddedMD&A
•for gene therapy programs, an increase primarily due to an increase in UX111 manufacturing costs in preparation for commercial launch, partially offset by the timing of the DTX401 and DTX301 manufacturing runs for which costs were incurred during the year ended December 31, 2024, which did not recur for the year ended December 31, 2025;
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
AddedMD&A
We expect a decrease in research and development expenses in the near term. This expected decline is primarily driven by the expected completion of several Phase 3 clinical programs and a strategic restructuring of our workforce and expenditures to better match our current pipeline requirements.
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
AddedMD&A
In November 2025, we received net proceeds of $392 million from OMERS for the sale of a percentage of our future royalties on Crysvita in the U.S. and Canada.
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
AddedMD&A
thereunder, and to further develop our general infrastructure and such funding may not be available to us on acceptable terms or at all.
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
AddedMD&A
Subsequent to December 31, 2025, we initiated a process to cancel certain arrangements with CMO’s related to the manufacturing of UX143. As a result, we expect that certain contract commitments will be cancelled and that the terminations will accelerate the net payments of approximately $40 million in accordance with the agreements. Our estimates are based on information available as of the approval date of the restructuring plan and are subject to change as the plan is implemented.
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
AddedMD&A
See "Note 2. Summary of Significant Accounting Policies" to the Consolidated Financial Statements for a discussion of recent accounting pronouncements.
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
AddedMD&A
The One Big Beautiful Bill Act, or OBBBA, was enacted in the U.S. in July 2025. The OBBBA legislation provides for the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, revisions to the international tax framework and the reinstatement of favorable tax treatment for certain business provisions. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented in future periods. We maintain a full valuation allowance against our U.S. federal and state deferred tax assets and does not anticipate achieving profitability to the extent needed to release the
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
AddedMD&A
valuation allowance in the near term. As such, we have determined that the OBBBA will not have a material impact on our income tax provision in the near term.
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
RemovedMD&A
As part of the process of preparing consolidated financial statements, we are required to estimate and accrue expenses, the largest of which is related to accrued research and development expenses. This process involves reviewing contracts and purchase orders, identifying services that have been performed on our behalf, and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual costs.
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedMD&A
We record accruals for estimated costs of research, preclinical and clinical studies, and manufacturing development. These costs are a significant component of our research and development expenses. A substantial portion of our ongoing research and development activities is conducted by third-party service providers. We accrue the costs incurred under our agreements with these third parties based on actual work completed in accordance with agreements established with these third parties. We determine the actual costs through discussions with internal personnel and external service providers as to the progress or stage of completion of the services and the agreed-upon fee to be paid for such services. We make judgments and estimates in determining the accrual balance in each reporting period. As actual costs become known, we adjust our accruals. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in us reporting amounts that are too high or too low in any particular period. Our accrual is dependent, in part, upon the receipt of timely and accurate reporting from clinical research organizations and other third-party vendors.
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedMD&A
Research and development costs are expensed as incurred and consist of salaries and benefits, stock-based compensation, lab supplies, materials and facility costs, as well as fees paid to other nonemployees and entities that conduct certain research and development activities on our behalf. Amounts incurred in connection with collaboration and license agreements are also included in research and development expense. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedMD&A
To date, there have been no material differences from our accrued estimated expenses to the actual clinical trial expenses; however, due to the nature of estimates, we cannot assure you that we will not make changes to our estimates in the future as we become aware of additional information about the status or conduct of our clinical studies and other research activities.
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedMD&A
We sell our approved products through a limited number of distributors. Under Accounting Standards Codification, or ASC, 606, Revenue from Contracts with Customers, revenue from product sales is recognized at the point in time when control is transferred to these distributors. We also recognize revenue from sales of certain products on a “named patient” basis, which are allowed in certain countries prior to the commercial approval of the product. Prior to recognizing revenue, we make estimates of the transaction price, including any variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved. Product sales are recorded net of estimated government-mandated rebates and chargebacks, estimated product returns, and other deductions.
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedMD&A
We have certain license and collaboration agreements that are within the scope of ASC 808, Collaborative Agreements, which provides guidance on the presentation and disclosure of collaborative arrangements. Generally, the classification of the transactions under the collaborative arrangements is determined based on the nature of contractual terms of the arrangement, along with the nature of the operations of the participants. We record our share of collaboration revenue, net of transfer pricing related to net sales in the period in which such sales occur, if we are considered as an agent in the arrangement. We are considered an agent when
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedMD&A
the collaboration partner controls the product before transfer to the customers and has the ability to direct the use of and obtain substantially all of the remaining benefits from the product. Funding received related to research and development services and commercialization costs is generally classified as a reduction of research and development expenses and selling, general and administrative expenses, respectively, in the Consolidated Statement of Operations, because the provision of such services for collaborative partners are not considered to be part of our ongoing major or central operations.
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedMD&A
We also record royalty revenues under certain of our license or collaboration agreements in exchange for license of intellectual property.
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedMD&A
We utilize certain information from our collaboration partners to record collaboration revenue, including revenue from the sale of the product, associated reserves on revenue, and costs incurred for development and sales activities. For the periods covered in the financial statements presented, there have been no material changes to prior period estimates of revenues and expenses.
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedMD&A
We record the royalty revenue from the net sales of Crysvita in the applicable territories on a prospective basis as non-cash royalty revenue in the Consolidated Statements of Operations over the term of the applicable arrangement.
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedMD&A
The terms of our collaboration and license agreements may contain multiple performance obligations, which may include licenses and research and development activities. We evaluate these agreements under ASC 606, Revenue from Contracts with Customers, to determine the distinct performance obligations. We analogize to ASC 606 for the accounting for distinct performance obligations for which there is a customer relationship. Prior to recognizing revenue, we make estimates of the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved. Total consideration may include nonrefundable upfront license fees, payments for research and development activities, reimbursement of certain third-party costs, payments based upon the achievement of specified milestones, and royalty payments based on product sales derived from the collaboration.
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RemovedMD&A
If there are multiple distinct performance obligations, we allocate the transaction price to each distinct performance obligation based on our relative standalone selling price. The standalone selling price is generally determined based on the prices charged to customers or using expected cost-plus margin. We estimate the efforts needed to complete the performance obligations and recognize revenue by measuring the progress towards complete satisfaction of the performance obligations using input measures.
Read it in 10-K Feb 19, 2025 at sec.govopen_in_new
RewordedMD&A
The change in operating assets and liabilities also reflected a net use of cash of $15.1 $23 million, primarily due to an increase in accounts receivable due to timing of sales and collections, combined with an increase in prepaid expense and other assets, primarily prepaid manufacturing, partially offset by an increase in accounts payable, accrued, and other liabilities, primarily related to an increase in sales of our approved products, partially offset by a net decrease accrued manufacturing in prepaid expenses preparation for development and other assets, primarily in prepaid manufacturing. commercial launches.
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
RewordedMD&A
Cash used in provided by investing activities for the year ended December 31, 2024 2025 was $17.8 $236 million and was primarily related to $12.5 proceeds of $258 million from net activities in marketable securities, partially offset by $15 million in payments for intangible assets related to milestones on our commercial products, partially offset by $4.7 million from net activities in marketable debt securities. products.
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
RewordedMD&A
Our Crysvita royalty revenue and collaboration revenue in the Profit-Share Territory increased by a net $22.5 million for the year ended December 31, 2024, compared to the same period in 2023; this This increase in Crysvita revenue is was primarily due to an increase in the number of patients on therapy.
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
RewordedMD&A
Cash provided by financing activities for the year ended December 31, 2023 2025 was $388.1 $478 million and was primarily comprised of $326.5 $392 million in net proceeds from the additional sale of common stock future royalties to OMERS in our October 2023 underwritten public offering and $53.3 November 2025, combined with $80 million in net proceeds from the issuance of common stock from our ATM. ATM offering.
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
RewordedMD&A
Our Crysvita royalty revenue and collaboration revenue in the Profit-Share Territory increased by a net $22.5 million for the year ended December 31, 2024, 2025, compared to the same period in 2023; this increase in Crysvita revenue is primarily due to an increase in the number of patients on therapy. 2024.
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
RewordedMD&A
We sold the our right to receive certain royalty payments from net sales of Crysvita in certain territories to RPI Finance Trust, or RPI, an Trust (an affiliate of Royalty Pharma, Pharma) and to OCM LS23 Holdings LP, an LP (an investment vehicle for Ontario Municipal Employees Retirement System, or OMERS, as further described in “Liabilities for Sales of Future Royalties” below. OMERS.
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
RewordedMD&A
We expect annual selling, general and administrative expenses to increase in the future as we continue plan to increase our selling expenses in preparation for launches of additional products, while continuing to support our existing approved products, products and multiple clinical-stage product candidates, and planned launches of additional products. candidates.
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
RewordedMD&A
The non-cash interest expense on liabilities for sales of future royalties decreased by $3.0 million for the year ended December 31, 2024, 2025, compared to the same period in 2023, 2024, primarily due to a reduction change in total estimate related to the timing of future royalty obligation balances as a result of increased royalties generated payments from our collaboration partner, KKC.
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
RewordedMD&A
The increase was primarily due to an increase in increased demand for Crysvita in Latin America resulting from an increase in the number of patients on therapy, ongoing continued progress of the launch of Evkeeza in Japan several markets in EMEA and in Europe, Middle East Japan, and Africa territories, or EMEA, and the continued increase in demand for our other approved products.
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
RewordedMD&A
We may require additional capital to fund our operations, to complete our ongoing and planned clinical studies, to commercialize our products, to continue investing in early-stage research capabilities to promote our pipeline growth, to continue to acquire or invest in businesses or products that complement or expand our business, including future milestone payments thereunder, and to further develop our general infrastructure and such funding may not be available to us on acceptable terms or at all.
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
RewordedMD&A
The increase in cost of sales was primarily due to an increase in demand for our approved products, primarily Crysvita in Latin America and America, Evkeeza in EMEA and Japan. Japan, and the continued increase in demand for our other approved products.
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
RewordedMD&A
Utilization of the net operating loss and tax credit carryforwards may be subject to an annual limitation due to historical or future ownership percentage change rules provided by the Internal Revenue Code of 1986, and similar state provisions.
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new
Quiet changesMD&A
The change in research and development expenses was primarily due to:
Read it in 10-K Feb 18, 2026 at sec.govopen_in_new